semaglutide 日本 Rybelsus (semaglutide) Japan Liraglutide and Semaglutide Market

Healthcare professionals are advised to prescribe semaglutide only within its licensed indications and to carefully assess patient suitability, including BMI criteria and presence of comorbidities

Additionally, clinical studies have generally shown that semaglutide results in a higher percentage of total body weight loss

Additionally, metabolic adaptations that occur during weight lossincluding reduced energy expenditure and hormonal changes that promote weight regainare no longer counteracted by the medication's effects

It is also prescribed for long-term weight management in adults and adolescents aged 12 years and older with obesity, and in adults with overweight who have a weight-related health condition